Policy & Regulation
PreveCeutical to begin clinical trials of cannabinoid Sol-Gel under the COVID-19 programme
6 August 2020 -

Health sciences company PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) stated on Wednesday that it plans to launch the clinical trials of its cannabinoid Sol-gel to reduce the possibility of contracting coronavirus infections.

In conjunction with the COVID-19 Sol-Gel clinical programme, the company has retained Veristat, a global clinical research organization (CRO) located in Massachusetts, USA, to assist with planning the clinical trial process and writing the required protocols.

Pursuant to the consulting agreement, Veristat will provide services to design and develop PreveCeutical COVID-19 Sol-Gel clinical programme and required protocol.



Related Headlines